MarginsXMarginsX
Home › Markets › Health Care › SPRB

Spruce Biosciences Inc. (SPRB)

SPRB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$42.25
-2.45% on the day
Market cap
$121.4M
Micro cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
-$39.0M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1683553/000119312526097558/0001193125-26-097558-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSPRB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001683553
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$39.0M
Operating income-$36.5M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$48.9M
Total assets$53.0M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
20.6 months
$87.7M cash at September 30, 2026
Share count, 1 year
+168.5%
2025-11-07 to 2026-11-05 · +39610.3% over 3 years
Going-concern doubt
Yes
10-Q filed November 9, 2026
Insider net buying, 12 months
-$336
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Accordingly, there is substantial doubt about the Company's ability to continue as a going concern for at least 12 months following the issuance date of these condensed consolidated financial statements."
10-Q 2026-11-09
Cash and burn$87.7M cash; operating cash flow -$12.8M a quarter.Report 2026-09-30
Shares outstanding2,874,013 (2026-11-05); 1,070,370 a year earlier; 40,710,692 three years earlier. 3y figure adjusted for splits (1-for-5625 overall).Cover page 2026-11-05
Reverse splits, 3 years2; latest 1-for-75 on 2025-08-07Source 2025-08-07
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-04-21
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBDO USA, P.C., San Jose, California, United StatesPCAOB Form AP 2026-03-12
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $5K, sold $5K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$24.0M-$13.8M$87.7M$19.5MNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
Not filed-$16.2M-$22.1M$96.3M$19.9MNeeds four quarters10-Q 2026-08-12
Q1 2026
2026-03-31
Not filed-$12.3M-$8.7M$54.1M$20.4MNeeds four quarters10-Q 2026-05-13
Q4 2025
2025-12-31
$0-$14.6M-$6.5M$48.9M$0$010-K 2026-03-09
Q3 2025
2025-09-30
$0-$8.2M-$5.3M$10.7M$549K$697K10-Q 2025-11-10
Q2 2025
2025-06-30
$0-$2.1M-$8.8M$16.4M$972K$1.3M10-Q 2025-08-14
Q1 2025
2025-03-31
$0-$14.0M-$12.7M$25.6M$1.4M$2.9M10-Q 2025-05-06
Q4 2024
2024-12-31
$697K-$23.6M-$20.7M$38.8M$1.8M$4.9M10-K 2026-03-09

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-04-21
Latest annual report10-K2026-03-09
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-09

Source: SEC EDGAR submissions feed, 369 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-7.0%
1 month+7.3%
3 months-13.0%
Year to date-50.3%
1 year-61.5%
From 52-week high-62.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
AKBAAkebia Therapeutics Inc.$0.4486-5.40%$124.6M
ALXOALX Oncology Holdings Inc.$1.00-3.85%$124.9M
UPBUpstream Bio Inc.$2.15-22.66%$117.8M
IMUXImmunic Inc.$7.23-3.86%$114.8M
PDSBPDS Biotechnology Corporation$0.9241+5.90%$113.4M
CNTNCanton Strategic Holdings Inc.$1.64-4.09%$130.7M
NTHINeOnc Technologies Holdings Inc.$4.54-7.54%$131.0M
CATXPerspective Therapeutics Inc.$0.9238-2.05%$111.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier